Home

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled...

Daniel Carlson -
2
TW's Take: BARDA is a great endorsement for the technology. TFFP's balance sheet issues notwithstanding, the value here for the tech is insane. Partnership funded...
Read more

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by...

Daniel Carlson -
0
TW's Take: more proof of the power of the TFF platform. If only funding were in place, the value here is crazy cheap. TFF-dry powder...
Read more

Take Two Aspirin and Call Me In The Morning

Daniel Carlson -
1
This week the market got the flu. Unfortunately, so did I. Perhaps the best way to deal with a weak market is from the sick...
Read more

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR...

Daniel Carlson -
0
TW's Take: giving the opening keynote address is a big honor and demonstrates just how exciting ANIX's CAR-T program is. The therapy continues to...
Read more

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

Daniel Carlson -
1
TW's Take: NVNO is making all the preparations for a big launch next year. Exciting times ahead for the company. MedTech Marketing Leader with Significant...
Read more

September Morn

Daniel Carlson -
6
This weekend I'm heading up to New York to watch the US Open. It's my first time going and I'm super excited. Albeit a...
Read more

Go Time! It’s All About Execution

Daniel Carlson -
2
The dramatic turnaround in the market after the swoon in early August continued this week with the indexes all making strong moves higher. For...
Read more

What Does It All Mean?

Daniel Carlson -
4
In the last two weeks we have seen markets collapse, only to rapidly recover lost ground. The spike in the volatility index was indicative...
Read more

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve®

Daniel Carlson -
0
TW's Take: the company is doing everything right as they march forward towards approval. VenoValve PMA Approval Application Process Consists of the Submission of 5...
Read more

No Respect

Daniel Carlson -
2
Rodney Dangerfield made a fortune out of playing the role of an underappreciated comedian. Famous for the line, "I get no respect," Dangerfield's skits...
Read more

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2...

Daniel Carlson -
0
TW's Take: a great update as TFF-TAC continues to demonstrate outstanding efficacy and safety. The drug has an increasingly high likelihood of being a...
Read more

Taking Chips Off The Table…

Daniel Carlson -
1
If you watch Texas Hold 'Em on TV, it's exciting. Lots of great hands, crazy bluffs and big pots. The game is exciting and...
Read more

Anixa Update for Premium Subscribers

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

PERMA-FIX ENVIRONMENTAL SERVICES ACQUIRES ENVIRONMENTAL WASTE OPERATIONS CENTER (EWOC) NEAR OAK RIDGE, TN

Daniel Carlson -
0
ATLANTA, July 30, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) announces it has acquired the Environmental Waste Operations Center...
Read more

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™...

Daniel Carlson -
0
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) --...
Read more

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International...

Daniel Carlson -
0
TW's Take: nice industry recognition for what is looking, in the early stages, like a very interesting therapy with great potential for Anixa. SAN JOSE,...
Read more

Russell 2000 Powerhouse? The Underdog Climbs Again!

Daniel Carlson -
0
Small cap stocks continue to put in a great rally, one that was long overdue. This past week saw the Russell 2000 gain 3%...
Read more

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the...

Daniel Carlson -
0
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics BOCA RATON, Fla., July 23,...
Read more

Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T...

Daniel Carlson -
4
TW's Take: this is a very positive outcome for someone in the lowest dose cohort of this trial. While we need to see this...
Read more

Shawn Thomas Joins Atomera as VP of Marketing and Business Development

Daniel Carlson -
0
TW's Take: nice to see they are optimistic enough to increase the burn and his joining is validation. Where are the partners? LOS GATOS, Calif.--(BUSINESS...
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.